{"id":"https://genegraph.clinicalgenome.org/r/14ea5963-3a52-4e78-a1e5-0c1b8cb356c7v1.1","type":"EvidenceStrengthAssertion","dc:description":"The *SCNN1G* gene is located on chromosome 16 at p12.2 and encodes the gamma subunit of the epithelial sodium channel (ENaC). The epithelial sodium channel is a heteromeric complex composed of the gamma subunit and two additional homologous subunits; alpha and beta, encoded by the *SCNN1A* and *SCNN1B* genes, respectively. The channel is localized in the apical portion of epithelial cells of the distal nephron, distal colon, lung, and ducts of exocrine glands (Canessa 1994 PMID: 8107805). It is crucial for Na+ reabsorption and, thus, electrolyte homeostasis (Hanukoglu 2016, PMID: 26772908). \n*SCNN1G* mutation was first reported in association with autosomal dominant Liddle Syndrome in 1995 (Hansson PMID:7550319). Liddle syndrome is characterized by early-onset (teenage) salt-sensitive hypertension. Laboratory evaluation shows hypokalemia, metabolic alkalosis, suppressed plasma renin activity and low plasma aldosterone (Tetti 2018 PMID: 29534496). \n*SCNN1G* mutation has also been reported in association with the autosomal recessive condition, Pseudohypoaldosteronism type I, and a Cystic Fibrosis-like condition referred to as ‘Bronchiectasis with or without elevated sweat chloride 3’ with an unclear inheritance pattern. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, there was sufficient phenotypic variability and differences in the molecular mechanisms to support splitting these disorders into three distinct disease entities; Liddle Syndrome (OMIM:618114), Pseudohypoaldosteronism type I (OMIM:264350) and Bronchiectasis with or without elevated sweat chloride 3 (OMIM:613071). Autosomal recessive Pseudohypoaldosteronism type I has been curated separately. \nAt least seven unique variants across as many publications have been reported in *SCNN1G* in association with Liddle Syndrome. Six of these variants cause a late truncation eliminating the PY domain and the seventh is a missense variant within the PY domain. Degradation of the protein via the ubiquitination-proteasomal pathway is mediated through the PY domain and loss of this domain allows the accumulation of ENaC in the distal nephron apical membrane leading to an increase in sodium reabsorption (Rotin 2008 PMID: 18691017). Probands with Liddle Syndrome and their families described in the literature display a consistent phenotype with variable expressivity and almost complete penetrance as one family displayed normokalemia and one parent, positive for the familial variant, was unaffected (Fan P 2020 PMID: 32161960). In addition, this gene-disease association is supported by expression studies and *in vitro* functional assays. The protein product has also been identified to co-localize with, bind to, and function with SCNN1B and SCNN1A (Duc 1994 PMID: 7806569, Stewart 2011. PMID: 21775436, Schild 1995 PMID: 7777572). \nIn summary, *SCNN1G* is definitively associated with autosomal dominant Liddle Syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/14ea5963-3a52-4e78-a1e5-0c1b8cb356c7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10067","date":"2022-04-05T12:39:25.031Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10067","date":"2021-06-17T02:30:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/455e27ad-82e5-4163-9cbb-892873aa895b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8e8be32f-8e5f-4af8-a785-e5b5304ef7b3","type":"Finding","dc:description":"In situ hydridization and Immunocytochemistry","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7806569","rdfs:label":"In situ hydridization and Immunocytochemistry","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ae7421d8-f697-4909-b604-315fe1b4da08","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d87f8959-a1a9-461a-8008-81b5d3e81c6c","type":"Finding","dc:description":"Three homologous subunits of the epithelial sodium channel","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21775436","rdfs:label":"Affinity chromatography and atomic Force Microscopy","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/04478227-c21a-4829-8618-470c6189cfd9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a4268cbf-7f55-4fd2-bed2-8e022fe3c8d9","type":"Finding","dc:description":"Phenotypes associated with salt re-absorption and electrolyte homeostasis.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9114818","rdfs:label":"Short-circuit current measurements","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0e2b3a44-8740-43f9-a322-bf042cde2653","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4bc25b45-e578-4089-ae2d-b62c40404345","type":"Finding","dc:description":"only heteromultimeric channels made of a, b, and g ENaC subunits are maximally and efficiently expressed at the cell surface\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8986818","rdfs:label":"Expression of ENaC in Xenopus Oocytes ","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e7bcaae-4269-48cd-8f19-86689788d681","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0dd9289b-c3c4-4da8-b933-c248281cd3c6","type":"FunctionalAlteration","dc:description":"Increase in sodium current","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7777572","rdfs:label":"Whole-Oocyte Macroscopic I-Na "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5dbc248c-4bf8-490d-b994-0c13f6848ecc","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5137ae0d-ae90-4c3c-8068-38c85043d18a","type":"FunctionalAlteration","dc:description":"Decreased sodium current","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10074483","rdfs:label":"Whole-Oocyte Macroscopic I-Na "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a5f82b28-3cd1-482b-baa8-84e9ca89dcc0","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a5f82b28-3cd1-482b-baa8-84e9ca89dcc0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32161960","allele":{"id":"https://genegraph.clinicalgenome.org/r/5bc03abc-7c64-4848-9e8b-f9bad5f8b514","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039.4(SCNN1G):c.1874C>T (p.Pro625Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395103981"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/43b5ba33-5457-4d82-af5b-c17062dba75a","type":"EvidenceLine","dc:description":"Truncation of the C terminus or mutation of the conserved C-terminal motif both result in increased surface expression of active sodium channels, leading to increased renal sodium absorption and creating a predisposition to hypertension - gain of function. \nIncreased expression due to impaired internalisation and degradation of the channel by the ubiquitination-proteasomal pathway (Snyder 1995, PMID: 8521520)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/43b5ba33-5457-4d82-af5b-c17062dba75a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17634077","allele":{"id":"https://genegraph.clinicalgenome.org/r/87eda205-c766-445c-87d4-407a38654ea2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039.4(SCNN1G):c.1749_1753del (p.Glu583fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/565277"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f0409e1b-7124-4497-aa75-2cbea5c17c71","type":"EvidenceLine","dc:description":"Truncation of the C terminus or mutation of the conserved C-terminal motif both result in increased surface expression of active sodium channels, leading to increased renal sodium absorption and creating a predisposition to hypertension - gain of function. \nIncreased expression due to impaired internalisation and degradation of the channel by the ubiquitination-proteasomal pathway (Snyder 1995, PMID: 8521520)\n","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0409e1b-7124-4497-aa75-2cbea5c17c71_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11228173","allele":{"id":"https://genegraph.clinicalgenome.org/r/fd7a8add-3606-4e64-bf6a-b02cbd7800c6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039.4(SCNN1G):c.1724G>A (p.Trp575Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395103539"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/60ce148e-eb8b-49c4-adec-ae98071f9cc2_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/789b23bd-a16d-449e-b413-95fdd3b55ac1_proband_segregation","type":"FamilyCosegregation","dc:description":"under 4 segregations","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30977777","rdfs:label":"Fan 2019","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/789b23bd-a16d-449e-b413-95fdd3b55ac1","type":"Family","rdfs:label":"Fan 2019","member":{"id":"https://genegraph.clinicalgenome.org/r/fead036a-d23f-491d-8f0d-da60937b5283","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30977777","rdfs:label":"III-4","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5d06b8ac-4ffb-48d2-b895-ffd0a7bcdd19","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039.4(SCNN1G):c.1756del (p.Arg586ValfsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573050812"}},"detectionMethod":"41 gene monogenic hypertension panel","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0000822","obo:HP_0003351","obo:HP_0040085"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e733afb9-3a33-40b4-99e1-2f0b139332f3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30977777","allele":{"id":"https://genegraph.clinicalgenome.org/r/5d06b8ac-4ffb-48d2-b895-ffd0a7bcdd19"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0003351","obo:HP_0040085","obo:HP_0000822"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/fead036a-d23f-491d-8f0d-da60937b5283"}},{"id":"https://genegraph.clinicalgenome.org/r/d47cf8f7-235a-4832-8832-90e80c219e86_proband_segregation","type":"FamilyCosegregation","dc:description":"Sequencing based on linkage analysis and candidate gene. Region of gene sequenced based on similarity to SCNN1G. Only known variants in transmembrane domain ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7550319","rdfs:label":"K204","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/d47cf8f7-235a-4832-8832-90e80c219e86","type":"Family","rdfs:label":"K204","member":{"id":"https://genegraph.clinicalgenome.org/r/9af8addc-0702-4a3e-9e66-bb021aaeac9a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7550319","rdfs:label":"1","allele":{"id":"https://genegraph.clinicalgenome.org/r/f0d89e18-783b-4752-bfb9-9a73fc811440","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039.4(SCNN1G):c.1718G>A (p.Trp573Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119950"}},"previousTesting":true,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a6b206fa-8235-4d78-8f71-fda1b2086818_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7550319","allele":{"id":"https://genegraph.clinicalgenome.org/r/f0d89e18-783b-4752-bfb9-9a73fc811440"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"low plasma aldosterone \nHypertension is early-onset\nHypokalemia not a constant finding","phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0002900","obo:HP_0000822","obo:HP_0003351"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/9af8addc-0702-4a3e-9e66-bb021aaeac9a"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/3edf8658-bd13-4441-9372-021cb7bbfb91_proband_segregation","type":"FamilyCosegregation","dc:description":"Gene-disease assertion already published","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26075967","rdfs:label":"III","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/3edf8658-bd13-4441-9372-021cb7bbfb91","type":"Family","rdfs:label":"III","member":{"id":"https://genegraph.clinicalgenome.org/r/0974e8f2-09cf-4f09-b10a-56e1f8aecc2d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26075967","rdfs:label":"III-1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5a039809-7efc-4493-8133-aa803bc80eb3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039.4(SCNN1G):c.1711G>T (p.Glu571Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA395103509"}},"phenotypes":["obo:HP_0003351","obo:HP_0000822","obo:HP_0200114","obo:HP_0002900","obo:HP_0040085"],"previousTesting":true,"previousTestingDescription":"SCNN1B exon 13","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b9e654cf-b753-48ef-897a-b2da5102f4fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26075967","allele":{"id":"https://genegraph.clinicalgenome.org/r/5a039809-7efc-4493-8133-aa803bc80eb3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0200114","obo:HP_0040085","obo:HP_0002900","obo:HP_0000822","obo:HP_0003351"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0974e8f2-09cf-4f09-b10a-56e1f8aecc2d"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/73bdcddf-0907-4065-a22d-97b28ad4a96f_proband_segregation","type":"FamilyCosegregation","dc:description":"under 4 segregations, dominant condition","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31655555","rdfs:label":"Kozina Family","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/73bdcddf-0907-4065-a22d-97b28ad4a96f","type":"Family","rdfs:label":"Kozina Family","member":{"id":"https://genegraph.clinicalgenome.org/r/f470d043-d2b3-4fc1-b26d-909940246dbe","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31655555","rdfs:label":"Koz","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2cf90782-e870-4ec3-b0dd-ec6aea240f0c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001039.4(SCNN1G):c.1769del (p.Gly590AlafsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573050811"}},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0200114","obo:HP_0003351","obo:HP_0002900","obo:HP_0000822"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d859246e-267c-4461-8b7e-ad188446441c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31655555","allele":{"id":"https://genegraph.clinicalgenome.org/r/2cf90782-e870-4ec3-b0dd-ec6aea240f0c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0002900","obo:HP_0000822","obo:HP_0200114","obo:HP_0003351"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/f470d043-d2b3-4fc1-b26d-909940246dbe"}},{"id":"https://genegraph.clinicalgenome.org/r/7d9fc293-6a56-4305-ae8f-2e76842d8254_proband_segregation","type":"FamilyCosegregation","dc:description":"Dominant condition under 4 segregations","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32161960","rdfs:label":"Fan","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/7d9fc293-6a56-4305-ae8f-2e76842d8254","type":"Family","rdfs:label":"Fan","member":{"id":"https://genegraph.clinicalgenome.org/r/8b1a63d0-1e60-4080-b60f-4a44f13d2bd8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32161960","rdfs:label":"III-3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5bc03abc-7c64-4848-9e8b-f9bad5f8b514"},"detectionMethod":"41 gene monogenic hypertension panel","phenotypes":["obo:HP_0003351","obo:HP_0040085","obo:HP_0002900","obo:HP_0000822"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a5f82b28-3cd1-482b-baa8-84e9ca89dcc0_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0040085","obo:HP_0002900","obo:HP_0003351","obo:HP_0000822"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/8b1a63d0-1e60-4080-b60f-4a44f13d2bd8"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/b9e654cf-b753-48ef-897a-b2da5102f4fc","type":"EvidenceLine","dc:description":"Truncation of the C terminus or mutation of the conserved C-terminal motif both result in increased surface expression of active sodium channels, leading to increased renal sodium absorption and creating a predisposition to hypertension - gain of function. \nIncreased expression due to impaired internalisation and degradation of the channel by the ubiquitination-proteasomal pathway (Snyder 1995, PMID: 8521520)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b9e654cf-b753-48ef-897a-b2da5102f4fc_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e733afb9-3a33-40b4-99e1-2f0b139332f3","type":"EvidenceLine","dc:description":"Truncation of the C terminus or mutation of the conserved C-terminal motif both result in increased surface expression of active sodium channels, leading to increased renal sodium absorption and creating a predisposition to hypertension - gain of function. \nIncreased expression due to impaired internalisation and degradation of the channel by the ubiquitination-proteasomal pathway (Snyder 1995, PMID: 8521520)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e733afb9-3a33-40b4-99e1-2f0b139332f3_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d859246e-267c-4461-8b7e-ad188446441c","type":"EvidenceLine","dc:description":"Truncation of the C terminus or mutation of the conserved C-terminal motif both result in increased surface expression of active sodium channels, leading to increased renal sodium absorption and creating a predisposition to hypertension - gain of function. \nIncreased expression due to impaired internalisation and degradation of the channel by the ubiquitination-proteasomal pathway (Snyder 1995, PMID: 8521520)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d859246e-267c-4461-8b7e-ad188446441c_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a6b206fa-8235-4d78-8f71-fda1b2086818","type":"EvidenceLine","dc:description":"loss or disruption of the PY motif prevents the degradation of the channel via the ubiquitination-proteasomal pathway and allows the accumulation of ENaC in the distal nephron apical membrane leading to an increase in sodium reabsorption ((Hanukoglu 2016, Rotin 2008, Schild 1995). Truncation of the C terminus or mutation of the conserved C-terminal motif both result in increased surface expression of active sodium channels, leading to increased renal sodium absorption and creating a predisposition to hypertension - gain of function. \nIncreased expression due to impaired internalisation and degradation of the channel by the ubiquitination-proteasomal pathway (Snyder 1995, PMID: 8521520)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a6b206fa-8235-4d78-8f71-fda1b2086818_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/a6b206fa-8235-4d78-8f71-fda1b2086818_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Oocytes expressing mutant yEN aC truncated at codon 574 display a 7.5-fold increase in amiloride sensitive sodium current compared with oocytes expressing wild-type channels (P=0.007; Fig. 5); this increase in channel activity is not distinguishable from the increased channel activity seen in control activated oocytes expressing truncated ~ENaC or yENaC truncated at codon 571 ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":10.1}],"evidenceStrength":"Definitive","sequence":4163,"specifiedBy":"GeneValidityCriteria8","strengthScore":13.1,"subject":{"id":"https://genegraph.clinicalgenome.org/r/cHt_yE2XvpQ","type":"GeneValidityProposition","disease":"obo:MONDO_0008323","gene":"hgnc:10602","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_60ce148e-eb8b-49c4-adec-ae98071f9cc2-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}